Paratek Pharmaceuticals - PRTK Stock Forecast, Price & News

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Paratek Pharmaceuticals in the last year. There are currently 1 buy rating and 1 strong buy rating for the stock. The consensus among Wall Street research analysts is that investors should "strong buy" PRTK shares.
View PRTK analyst ratings or view top-rated stocks.

2 Wall Street research analysts have issued 12-month price targets for Paratek Pharmaceuticals' shares. Their PRTK share price forecasts range from $11.00 to $30.00. On average, they anticipate the company's share price to reach $20.33 in the next twelve months. This suggests a possible upside of 787.9% from the stock's current price.
View analysts price targets for PRTK or view top-rated stocks among Wall Street analysts.

Paratek Pharmaceuticals' stock was trading at $4.49 at the beginning of the year. Since then, PRTK stock has decreased by 49.0% and is now trading at $2.29.
View the best growth stocks for 2022 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, November 14th 2022.
View our PRTK earnings forecast.

Paratek Pharmaceuticals, Inc. (NASDAQ:PRTK) issued its earnings results on Monday, November, 8th. The specialty pharmaceutical company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($0.45) by $0.08. The specialty pharmaceutical company had revenue of $24.45 million for the quarter, compared to analysts' expectations of $22.98 million. During the same period in the prior year, the company posted ($0.46) EPS.

Paratek Pharmaceuticals updated its FY 2022 earnings guidance on Wednesday, August, 10th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $155.00 million-$170.00 million, compared to the consensus revenue estimate of $163.89 million.

Based on aggregate information from My MarketBeat watchlists, some companies that other Paratek Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Dynavax Technologies (DVAX), Matinas BioPharma (MTNB), CBL & Associates Properties (CBL), Inovio Pharmaceuticals (INO), ADMA Biologics (ADMA), Aduro Biotech (ADRO), Corbus Pharmaceuticals (CRBP) and Rigel Pharmaceuticals (RIGL).

Paratek Pharmaceuticals trades on the NASDAQ under the ticker symbol "PRTK."

Paratek Pharmaceuticals' stock is owned by many different retail and institutional investors. Top institutional investors include General American Investors Co. Inc. (3.22%), Millennium Management LLC (0.92%), 1492 Capital Management LLC (0.89%), Pictet Asset Management SA (0.88%), Renaissance Technologies LLC (0.54%) and State Street Corp (0.39%). Insiders that own company stock include Adam Woodrow, Evan Loh, Michael Bigham, Randall B Brenner and William M Haskel.
View institutional ownership trends.

Shares of PRTK stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of PRTK stock can currently be purchased for approximately $2.29.

Paratek Pharmaceuticals (NASDAQ:PRTK) has a market capitalization of $125.64 million and generates $130.16 million in revenue each year. The specialty pharmaceutical company earns $-59,080,000.00 in net income (profit) each year or ($1.69) on an earnings per share basis.

The company employs 207 workers across the globe.

Paratek Pharmaceuticals' mailing address is 75 PARK PLAZA, BOSTON MA, 02116. The official website for the company is www.paratekpharma.com. The specialty pharmaceutical company can be reached via phone at (617) 807-6600, via email at ir@paratekpharma.com, or via fax at 617-275-0039.